- Home
- MHUA vs SABS Comparison
MHUA vs SABS Comparison
Compare MHUA & SABS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MHUA
- SABS
- Stock Information
- Founded
- MHUA 1990
- SABS 2014
- Country
- MHUA China
- SABS United States
- Employees
- MHUA N/A
- SABS N/A
- Industry
- MHUA Medical Specialities
- SABS Biotechnology: Pharmaceutical Preparations
- Sector
- MHUA Health Care
- SABS Health Care
- Exchange
- MHUA Nasdaq
- SABS Nasdaq
- Market Cap
- MHUA 19.6M
- SABS 15.8M
- IPO Year
- MHUA 2022
- SABS N/A
- Fundamental
- Price
- MHUA $0.41
- SABS $2.19
- Analyst Decision
- MHUA
- SABS Strong Buy
- Analyst Count
- MHUA 0
- SABS 5
- Target Price
- MHUA N/A
- SABS $10.00
- AVG Volume (30 Days)
- MHUA 94.8K
- SABS 145.3K
- Earning Date
- MHUA 09-19-2025
- SABS 08-07-2025
- Dividend Yield
- MHUA N/A
- SABS N/A
- EPS Growth
- MHUA N/A
- SABS N/A
- EPS
- MHUA 0.40
- SABS N/A
- Revenue
- MHUA $96,909,642.00
- SABS $114,698.00
- Revenue This Year
- MHUA N/A
- SABS N/A
- Revenue Next Year
- MHUA N/A
- SABS N/A
- P/E Ratio
- MHUA $1.04
- SABS N/A
- Revenue Growth
- MHUA N/A
- SABS N/A
- 52 Week Low
- MHUA $0.25
- SABS $1.00
- 52 Week High
- MHUA $1.26
- SABS $6.60
- Technical
- Relative Strength Index (RSI)
- MHUA 52.15
- SABS 50.13
- Support Level
- MHUA $0.39
- SABS $1.97
- Resistance Level
- MHUA $0.42
- SABS $2.25
- Average True Range (ATR)
- MHUA 0.03
- SABS 0.13
- MACD
- MHUA 0.00
- SABS -0.02
- Stochastic Oscillator
- MHUA 72.00
- SABS 56.18
About MHUA Meihua International Medical Technologies Co. Ltd.
Meihua International Medical Technologies Co Ltd is engaged in providing disposable medical devices. It serves hospitals, pharmacies, medical institutions, and medical equipment companies. Its product offerings include a Disposable Medical mask, Disposable ID Bracelet, Disposable Artificial Anal bag, Disposable Catheter, and Electonic pump among others.
About SABS SAB Biotherapeutics Inc.
SAB Biotherapeutics Inc is a clinical stage biopharmaceutical company focused on the development and commercialization of a portfolio of products from its proprietary immunotherapy platform to produce fully targeted human polyclonal antibodies, without using human plasma or serum. The company's novel DiversitAb platform enables the rapid production of large amounts of targeted human polyclonal antibodies, leveraging transchromosomic cattle (Tc Bovine) that have been genetically designed to produce human antibodies (immunoglobulin G) rather than bovine in response to an antigen. Animal antibodies have been made in rabbits, sheep and horses.